Literature DB >> 8480348

Lack of clinical significance of "enzyme-only" red cell alloantibodies.

P D Issitt1, M R Combs, S J Bredehoeft, M L Campbell, M Heimer, L Joyner, L Lorentsen, C Remley, S Bullock, J Bumgarner.   

Abstract

In a retrospective study on samples from 10,000 recently transfused patients, 35 samples were found to contain an antibody that reacted with ficin-treated red cells but was not demonstrable by low-ionic-strength saline solution and indirect antiglobulin test (LISS-IAT). In those 35 patients, the specificity of the antibody was such that each patient would have been transfused with antigen-negative blood had the antibody reacted in LISS-IAT. Tests on red cells from the units already transfused showed that 19 patients had among them received, by chance, 32 antigen-positive and 74 antigen-negative units. The remaining 16 patients had among them received 57 units that were, again by chance, all antigen negative. One patient given antigen-positive blood suffered a delayed transfusion reaction; in two others the antibodies became LISS-IAT active after transfusion. However, similar changes to the LISS-IAT-active state were seen with two antibodies of patients given only antigen-negative blood. Also found in the 10,000 patients were 28 clinically insignificant antibodies, 77 sera in which the antibody was too weak to identify, and 216 autoantibodies that reacted only with ficin-treated red cells. These data support a belief, generally held in the United States but not necessarily elsewhere, that the use of protease-treated red cells for routine pretransfusion tests creates far more work than the accrued benefits justify.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8480348     DOI: 10.1046/j.1537-2995.1993.33493242634.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  8 in total

1.  Role of enzyme-treated cells in RBC antibody screening using the gel test: a study of anti-RH1, -RH2, and -RH3 antibodies.

Authors:  Jocelyne Conne; Philippe Schneider; Jean-Daniel Tissot
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

2.  Consequences for fetus and neonate of maternal red cell allo-immunisation.

Authors:  H Howard; V Martlew; I McFadyen; C Clarke; J Duguid; I Bromilow; J Eggington
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-01       Impact factor: 5.747

3.  Evaluation of a modified IAT-gel with polyethylenglycol (PEG) addition method for red blood cell antibody identification.

Authors:  L Gustafsson; A Wikman; J Lundahl
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

4.  Frequencies and specificities of "enzyme-only" detected erythrocyte alloantibodies in patients hospitalized in austria: is an enzyme test required for routine red blood cell antibody screening?

Authors:  Dietmar Enko; Claudia Habres; Franz Wallner; Barbara Mayr; Gabriele Halwachs-Baumann
Journal:  J Blood Transfus       Date:  2014-03-25

5.  Comparison of Tube, Gel, and Immunochromatographic Strip Methods for Evaluation of Blood Transfusion Compatibility in Horses.

Authors:  D Luethy; S D Owens; D Stefanovski; R Nolen-Walston; U Giger
Journal:  J Vet Intern Med       Date:  2016-10-22       Impact factor: 3.333

6.  Screening and identification of unexpected red cell antibodies by simultaneous LISS/Coombs and NaCl/Enzyme gel methods.

Authors:  Jeong Hwan Shin; Ja Young Lee; Jae Hyen Kim; Hye Ran Kim; Jeong Nyeo Lee
Journal:  J Korean Med Sci       Date:  2009-07-29       Impact factor: 2.153

7.  Unexpected red cell antibody detection by conditional combination of LISS/Coombs and NaCl/Enzyme gel tests at a tertiary care hospital in Korea: A 5-year study.

Authors:  Jeong Won Shin
Journal:  Blood Res       Date:  2013-09-25

8.  Comparison of two column agglutination tests for red blood cell antibody testing.

Authors:  Jonas Sawierucha; Marion Posset; Viola Hähnel; Christian L Johnson; James A Hutchinson; Norbert Ahrens
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.